Clinical trial · Observational
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer Via Analysis of Immunoinflammation-related Protein Complexes in Blood
NCT04145960CI-TRIAL-00041694unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The relationship between immune inflammation-related protein complexes in blood and recurrence or metastasis of breast cancer will be studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Lymph node metastasis
- description
- Axillary lymph node metastasis ≥ 4 Lymph nodes
Primary outcomes (2)
- measure
- immune inflammation-related protein complexes
- timeFrame
- 2 years
- description
- The change of immune inflammation-related protein complexes which is measured by gel permeation chromatography.
- measure
- blood markers
- timeFrame
- 2 years
- description
- The expression of CA153, CEA, CA125 in the blood of the patients, which are measured by electro-chemiluminescence immunoassay.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Female * Postoperative pathology confirmed invasive breast cancer after surgery for breast tumors * Breast cancer-related chemotherapy and radiotherapy completed * axillary lymph node metastasis ≥ 4 * age ≤ 60 years old Exclusion Criteria: * Male * Aged above 60 * Breast Carcinoma in situ * Women in pregnancy or breastfeeding * Suffering from other malignant tumors * Non-compliant patient
References
Publications (0)
Data not yet available
No reference posted for this study.